-
![Methyl 2-(Fluoromethyl)-5-Oxo-4-Phenyl-4,5,6,7-Tetrahydro-1h-Cyclopenta[B]Pyridine-3-Carboxylate And Methyl 2- (Fluoromethyl0-5-Oxo-4-Phenyl-1,4,5,7-Tetrahydrofuro[3,4-B]Purodine-3-Carboxylate As Cav1.2 Activators](/abs-image/US/2025/01/02/US20250002499A1/abs.jpg.150x150.jpg)
公开(公告)号：US20250002499A1
公开(公告)日：2025-01-02
申请号：US18422517
申请日：2024-01-25
Applicant: Novartis AG
Inventor： Sung David C. Kim , Zaixing Li , Chui Lu , Danuta Lubicka , James Neef , Hye-Yeon Park , Tejaskumar Pankajbhai Pathak , Amir Masoud Sadaghiani , Xilin Zhou
IPC: C07D491/048 , C07D221/04
Abstract: The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as CaV1.22 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, or early repolarization syndrome.
-
![Methyl (r)-2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1H-cyclopenta[b]pyridine-3-carboxylate and methyl (r)-2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyridine-3-carboxylate as CAV1.2 activators](/abs-image/US/2024/03/05/US11919911B2/abs.jpg.150x150.jpg)
公开(公告)号：US11919911B2
公开(公告)日：2024-03-05
申请号：US17346006
申请日：2021-06-11
Applicant: Novartis AG
Inventor： Sung David C. Kim , Zaixing Li , Chui Lu , Danuta Lubicka , James Neef , Hye-Yeon Park , Tejaskumar Pankajbhai Pathak , Amir Masoud Sadaghiani , Xilin Zhou
IPC: C07D491/048 , C07D221/04
CPC classification number: C07D491/048 , C07D221/04 , C07B2200/13
Abstract: The present disclosure provides for a compound according to formula (I)
or a pharmaceutically acceptable salt thereof as CaV1.22 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, or early repolarization syndrome.-
![METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-4,5,6,7-TETRAHYDRO-1H-CYCLOPENTA[B]PYRIDINE-3-CARBOXYLATE AND METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-1,4,5,7-TETRAHYDROFURO[3,4-B]PYRIDINE-3-CARBOXYLATE AS CAV1.2 ACTIVATORS](/abs-image/US/2021/12/23/US20210395261A1/abs.jpg.150x150.jpg)
公开(公告)号：US20210395261A1
公开(公告)日：2021-12-23
申请号：US17346006
申请日：2021-06-11
Applicant: Novartis AG
Inventor： Sung David C. Kim , Zaixing Li , Chui Lu , Danuta Lubicka , James Neef , Hye-Yeon Park , Tejaskumar Pankajbhai Pathak , Amir Masoud Sadaghiani , Xilin Zhou
IPC: C07D491/048 , C07D221/04
Abstract: The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as CaV1.22 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, or early repolarization syndrome.
-
-
Search Results
3
records
(took 0.035 seconds)
